Ifyltan

Fentanyl, the active ingredient in Ifyltan, is an opioid analgesic presented as an oral formulation for oral use. Approved in the European Union, the product is intended for prescription‑only use under medical supervision and is indicated for the management of severe pain, including cancer‑related pain, in patients who require strong, continuous analgesia.

GNH USA supplies Ifyltan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global logistics to meet the needs of healthcare providers across multiple regions.

Ifyltan (fentanyl) acts on the mu‑opioid receptor pathway to provide potent analgesia for severe pain conditions.

Severe pain: delivers strong, continuous relief for patients with intense acute or chronic pain. Cancer pain: controls malignant disease‑related pain that is unresponsive to weaker opioids. Breakthrough cancer pain: provides rapid relief for episodic spikes in pain despite baseline opioid therapy.

Fentanyl may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Constipation - Drowsiness or sedation - Dizziness or light‑headedness - Dry mouth - Sweating

Serious or Rare Side Effects: - Respiratory depression, which can be life‑threatening - Severe hypotension or cardiovascular collapse - Chest wall rigidity - Development of physical dependence or addiction - Overdose leading to coma or death - Adrenal insufficiency

When prescribing or dispensing Ifyltan, several safety considerations should be observed. - Assess respiratory function: ensure adequate ventilation before initiating therapy. - Evaluate opioid tolerance: confirm the patient is opioid‑experienced to reduce overdose risk. - Monitor for signs of dependence: watch for cravings, withdrawal, or misuse behaviors. - Avoid use in severe asthma or uncontrolled respiratory disease. - Adjust dose in hepatic impairment: reduced clearance may increase plasma levels. - Store at ambient temperature: keep in the original packaging, protect from moisture and light.

Fentanyl can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concomitant central nervous system depressants (e.g., benzodiazepines, barbiturates) may cause profound respiratory depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase fentanyl plasma concentrations.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., erythromycin) may modestly raise fentanyl levels. - CNS stimulants (e.g., tramadol) can increase seizure risk. - MAO inhibitors: concurrent use may precipitate hypertensive crises or serotonin syndrome.